Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Clinical trial NCT07024706 · RECRUITING

Trial details

NCT number: NCT07024706
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Start date: 2026-06-04
Primary completion: 2029-05-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.